Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib

Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor‐positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Miettinen, Teemu P, Peltier, Julien, Härtlova, Anetta, Gierliński, Marek, Jansen, Valerie M, Trost, Matthias, Björklund, Mikael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978322/
https://www.ncbi.nlm.nih.gov/pubmed/29669860
http://dx.doi.org/10.15252/embj.201798359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978322/
https://www.ncbi.nlm.nih.gov/pubmed/29669860
http://dx.doi.org/10.15252/embj.201798359

Ejemplares similares